Who
Lisa von Moltke
Officer
Company insider
Files Form 4 as: Officer, Zenas BioPharma; Officer, Seres Therapeutics; Director, Tvardi Therapeutics.
In numbers
- Trades disclosed
- 41
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $19K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 6 Apr 2020
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 15 Apr 2025filed 17 Apr 2025 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 18 Feb 2025filed 19 Feb 2025 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,5774,416 at $0.81 | filing |
| 15 Feb 2025filed 19 Feb 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,969 at $0.00 | filing |
| 15 Feb 2025filed 19 Feb 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,907 at $0.00 | filing |
| 15 Feb 2025filed 19 Feb 2025 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,969 | filing |
| 15 Feb 2025filed 19 Feb 2025 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —8,907 | filing |
| 7 Feb 2025filed 11 Feb 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650,000 at $0.00 | filing |
| 18 Nov 2024filed 19 Nov 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $528977 at $0.54 | filing |
| 15 Nov 2024filed 19 Nov 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,969 at $0.00 | filing |
| 15 Nov 2024filed 19 Nov 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,969 | filing |
| 28 Oct 2024filed 29 Oct 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9904,334 at $0.69 | filing |
| 27 Oct 2024filed 29 Oct 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,744 at $0.00 | filing |
| 27 Oct 2024filed 29 Oct 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,744 at $0.00 | filing |
| 16 Aug 2024filed 19 Aug 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $817973 at $0.84 | filing |
| 15 Aug 2024filed 19 Aug 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,969 at $0.00 | filing |
| 15 Aug 2024filed 19 Aug 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,969 | filing |
| 4 Jun 2024filed 6 Jun 2024 | TVRD Tvardi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | TVRD Tvardi TherapeuticsBiotechnology | SEC FORM 4 Code A | —150,647 at $0.00 | filing |
News
Critical Contrast: Seres Therapeutics (NASDAQ:MCRB) & BioLineRx (NASDAQ:BLRX)MCRB · tickerreport.com · 21 Oct 2026MDxHealth (NASDAQ:MDXH) versus Seres Therapeutics (NASDAQ:MCRB) Financial ComparisonMCRB · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Lisa von Moltke; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.